| Autor: |
Hernández-Aceves, Juan A., Cervantes-Torres, Jacquelynne, Torres-García, Diana, Zuñiga-Flores, Francisco J., Patiño-Chávez, Osiris J., Peña Agudelo, Jorge A., Aguayo-Flores, José Eduardo, Garfias, Yonathan, Montero-León, Laura, Romero-Romero, Laura, Pérez-Torres, Armando, Fragoso, Gladis, Sciutto, Edda |
| Předmět: |
|
| Zdroj: |
Cancer Immunology, Immunotherapy; Nov2023, Vol. 72 Issue 11, p3825-3838, 14p |
| Abstrakt: |
Breast cancer is the leading malignancy in women worldwide, both in terms of incidence and mortality. Triple-negative breast cancer (TNBC) is the type with the worst clinical outcomes and with fewer therapeutic options than other types of breast cancer. GK-1 is a peptide that in the experimental model of the metastatic 4T1 breast cancer has demonstrated anti-tumor and anti-metastatic properties. Herein, GK-1 (5 mg/kg, i.v.) weekly administrated not only decreases tumor growth and the number of lung macro-metastases but also lung and lymph nodes micro-metastases. Histological analysis reveals that GK-1 reduced 57% of the intra-tumor vascular areas, diminished the leukemoid reaction's progression, and the spleens' weight and length. A significant reduction in VEGF-C, SDF-1, angiopoietin-2, and endothelin-1 angiogenic factors was induced. Moreover, GK-1 prevents T cell exhaustion in the tumor-infiltrating lymphocytes (TILs) decreasing PD-1 expression. It also increased IFN-γ and granzyme-B expression and the cytotoxic activity of CD8+ TILs cells against tumor cells. All these features were found to be associated with a better antitumor response and prognosis. Altogether, these results reinforce the potential of GK-1 to improve the clinical outcome of triple-negative breast cancer immunotherapy. Translation research is ongoing towards its evaluation in humans. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink